Last reviewed · How we verify
Sandimmune® Injection
Sandimmune (cyclosporine) suppresses T-cell activation and proliferation by inhibiting calcineurin, thereby reducing immune-mediated rejection and inflammatory responses.
Sandimmune (cyclosporine) suppresses T-cell activation and proliferation by inhibiting calcineurin, thereby reducing immune-mediated rejection and inflammatory responses. Used for Prevention of organ rejection in transplant recipients (kidney, heart, liver, pancreas), Severe active rheumatoid arthritis, Severe psoriasis.
At a glance
| Generic name | Sandimmune® Injection |
|---|---|
| Sponsor | NeuroVive Pharmaceutical AB |
| Drug class | Calcineurin inhibitor |
| Target | Calcineurin (via cyclophilin binding) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Cyclosporine binds to cyclophilin and forms a complex that inhibits calcineurin phosphatase, blocking the dephosphorylation of nuclear factor of activated T cells (NFAT). This prevents T-cell activation, IL-2 production, and proliferation of T lymphocytes. The drug is used primarily to prevent organ transplant rejection and treat autoimmune conditions by suppressing cellular immunity.
Approved indications
- Prevention of organ rejection in transplant recipients (kidney, heart, liver, pancreas)
- Severe active rheumatoid arthritis
- Severe psoriasis
- Nephrotic syndrome
Common side effects
- Nephrotoxicity/renal dysfunction
- Hypertension
- Tremor
- Gingival hyperplasia
- Hirsutism
- Headache
- Infection
- Hyperkalemia
Key clinical trials
- TRACK-TBI Precision Medicine Part 3 - Option II (PHASE2)
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
- Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy (PHASE2)
- Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders (PHASE2)
- Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia (PHASE1, PHASE2)
- A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable (PHASE3)
- Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source (PHASE1)
- 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |